{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:38:39Z","timestamp":1771623519700,"version":"3.50.1"},"reference-count":93,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020, UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020, UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50006\/2020, PTDC\/BTM-SAL\/29786\/2017"],"award-info":[{"award-number":["UIDB\/50006\/2020, PTDC\/BTM-SAL\/29786\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Toxoplasmosis is a parasitic disease caused by the globally distributed protozoan parasite Toxoplasma gondii, which infects around one-third of the world population. This disease may result in serious complications for fetuses, newborns, and immunocompromised individuals. Current treatment options are old, limited, and possess toxic side effects. Long treatment durations are required since the current therapeutic system lacks efficiency against T. gondii tissue cysts, promoting the establishment of latent infection. This review highlights the most promising drug targets involved in anti-T. gondii drug discovery, including the mitochondrial electron transport chain, microneme secretion pathway, type II fatty acid synthesis, DNA synthesis and replication and, DNA expression as well as others. A description of some of the most promising compounds demonstrating antiparasitic activity, developed over the last decade through drug discovery and drug repurposing, is provided as a means of giving new perspectives for future research in this field.<\/jats:p>","DOI":"10.3390\/microorganisms9091960","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T12:00:44Z","timestamp":1631707244000},"page":"1960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-1446","authenticated-orcid":false,"given":"Marco da","family":"Silva","sequence":"first","affiliation":[{"name":"Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia da Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-3781","authenticated-orcid":false,"given":"C\u00e1tia","family":"Teixeira","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias da Universidade do Porto, 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-4724","authenticated-orcid":false,"given":"Paula","family":"Gomes","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias da Universidade do Porto, 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-4095","authenticated-orcid":false,"given":"Margarida","family":"Borges","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"ref_1","unstructured":"Weiss, L.M., and Kim, K. (2020). Chapter 6\u2014Toxoplasmosis in wild and domestic animals. Toxoplasma Gondii, Academic Press. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-020-3954-1","article-title":"The global serological prevalence of Toxoplasma gondii in felids during the last five decades (1967\u20132017): A systematic review and meta-analysis","volume":"13","author":"Montazeri","year":"2020","journal-title":"Parasit. Vectors"},{"key":"ref_3","first-page":"898","article-title":"Global status of Toxoplasma gondii infection: Systematic review and prevalence snapshots","volume":"36","author":"Molan","year":"2019","journal-title":"Trop. Biomed."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/MMBR.00027-15","article-title":"Long-Term Relationships: The Complicated Interplay between the Host and the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections","volume":"79","author":"Pittman","year":"2015","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.pt.2005.08.001","article-title":"Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host","volume":"21","author":"Saeij","year":"2005","journal-title":"Trends Parasitol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/apha.12458","article-title":"Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases","volume":"213","author":"Xiao","year":"2015","journal-title":"Acta Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"R770","DOI":"10.1016\/j.cub.2018.05.035","article-title":"Toxoplasma gondii","volume":"28","author":"Kochanowsky","year":"2018","journal-title":"Curr. Biol."},{"key":"ref_8","unstructured":"Ryan, E.T., Hill, D.R., Solomon, T., Aronson, N.E., and Endy, T.P. (2020). 106\u2014Toxoplasmosis. Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases, Content Repository Only. [10th ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1017\/S0031182016001785","article-title":"Impaired health status and increased incidence of diseases in Toxoplasma-seropositive subjects\u2014An explorative cross-sectional study","volume":"143","author":"Flegr","year":"2016","journal-title":"Parasitology"},{"key":"ref_10","first-page":"389","article-title":"Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/jpids\/piu077","article-title":"Congenital Toxoplasmosis","volume":"3","author":"McAuley","year":"2014","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0002-9378(99)70224-3","article-title":"Treatment of toxoplasmosis during pregnancy: A multicenter study of impact on fetal transmission and children\u2019s sequelae at age 1 year","volume":"180","author":"Foulon","year":"1999","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/B978-0-444-52910-7.00028-3","article-title":"Congenital toxoplasmosis","volume":"112","author":"Kieffer","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/IAI.05899-11","article-title":"Tissue barriers of the human placenta to infection with Toxoplasma gondii","volume":"80","author":"Robbins","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejogrb.2020.10.003","article-title":"Toxoplasmosis in pregnancy","volume":"255","author":"Ahmed","year":"2020","journal-title":"Eur J. Obs. Gynecol. Reprod. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12606","DOI":"10.1111\/pim.12606","article-title":"How does toxoplasmosis affect the maternal-foetal immune interface and pregnancy?","volume":"41","author":"Borges","year":"2019","journal-title":"Parasite Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/09273948.2013.779724","article-title":"Therapy for ocular toxoplasmosis--The future","volume":"21","author":"Garweg","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.parint.2018.07.004","article-title":"Congenital toxoplasmosis: An overview of the neurological and ocular manifestations","volume":"67","author":"Khan","year":"2018","journal-title":"Parasitol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbi.2019.01.026","article-title":"Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders","volume":"79","author":"Burgdorf","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.encep.2012.06.014","article-title":"Toxoplasma gondii: A potential role in the genesis of psychiatric disorders","volume":"39","author":"Fond","year":"2013","journal-title":"L\u2019Enc\u00e9phale"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.psychres.2019.06.031","article-title":"Relationship between Toxoplasma gondii seropositivity and depression in children and adolescents","volume":"278","author":"Kandemir","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.17219\/acem\/61435","article-title":"Relationship between toxoplasmosis and schizophrenia: A review","volume":"26","author":"Fuglewicz","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12776","DOI":"10.5812\/jjm.18789","article-title":"Toxoplasma gondii Exposure and the Risk of Schizophrenia","volume":"7","author":"Khademvatan","year":"2014","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/acps.12423","article-title":"Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis","volume":"132","author":"Sutterland","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dunay, I.R., Gajurel, K., Dhakal, R., Liesenfeld, O., and Montoya, J.G. (2018). Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice. Clin. Microbiol. Rev., 31.","DOI":"10.1128\/CMR.00057-17"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1086\/590149","article-title":"Management of Toxoplasma gondii infection during pregnancy","volume":"47","author":"Montoya","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DDDT.S60973","article-title":"Drugs in development for toxoplasmosis: Advances, challenges, and current status","volume":"11","author":"Alday","year":"2017","journal-title":"Drug Des. Devel."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1701-2163(15)31053-7","article-title":"Toxoplasmosis in pregnancy: Prevention, screening, and treatment","volume":"35","author":"Paquet","year":"2013","journal-title":"J. Obs. Gynaecol. Can."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e240809","DOI":"10.1136\/bcr-2020-240809","article-title":"What obstetricians should be aware of: Serious side effects of antibiotic toxoplasmosis treatment in pregnancy","volume":"14","author":"Ardabili","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review","volume":"17","author":"Goodwin","year":"2017","journal-title":"Drugs R D"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/5584_2018_262","article-title":"Adverse Reactions in Antifolate-Treated Toxoplasmic Retinochoroiditis","volume":"1108","author":"Borkowski","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/trstmh\/try040","article-title":"Ocular toxoplasmosis: Adverse reactions to treatment in a Brazilian cohort","volume":"112","author":"Guaraldo","year":"2018","journal-title":"Trans. R Soc. Trop Med. Hyg."},{"key":"ref_33","first-page":"1415","article-title":"Adverse Reactions with Antitoxoplasma Therapy","volume":"44","author":"Iaccheri","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41598-020-80569-7","article-title":"Adverse outcomes associated with the treatment of Toxoplasma infections","volume":"11","author":"Shammaa","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","article-title":"Antibiotics for human toxoplasmosis: A systematic review of randomized trials","volume":"107","author":"Rajapakse","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1016\/j.jogc.2018.05.036","article-title":"No. 285-Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment","volume":"40","author":"Paquet","year":"2018","journal-title":"J. Obs. Gynaecol. Can."},{"key":"ref_37","unstructured":"(2021, September 06). Dexamethasone for Cerebral Toxoplasmosis-ClinicalTrials.gov Identifier: NCT04341155, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04341155."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1016\/j.fawpar.2019.e00036","article-title":"Treatment of toxoplasmosis: Current options and future perspectives","volume":"15","author":"Konstantinovic","year":"2019","journal-title":"Food Waterborne Parasitol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.exppara.2012.11.019","article-title":"Induction of sulfadiazine resistance in vitro in Toxoplasma gondii","volume":"133","author":"Doliwa","year":"2013","journal-title":"Exp. Parasitol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/AAC.01203-07","article-title":"In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone","volume":"52","author":"Meneceur","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Silva, L.A., Reis-Cunha, J.L., Bartholomeu, D.C., and V\u00edtor, R.W.A. (2017). Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170689"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.3389\/fimmu.2020.621997","article-title":"Vaccines in Congenital Toxoplasmosis: Advances and Perspectives","volume":"11","author":"Barros","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/AAC.01823-13","article-title":"Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii","volume":"58","author":"Doggett","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1021\/acs.jmedchem.6b00760","article-title":"Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis","volume":"59","author":"Vidadala","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.7b01192","article-title":"Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii","volume":"60","author":"Rutaganira","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0020-7519(01)00111-4","article-title":"Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I","volume":"31","author":"McLeod","year":"2001","journal-title":"Int. J. Parasitol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exppara.2014.12.007","article-title":"Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis","volume":"149","author":"Mossallam","year":"2015","journal-title":"Exp. Parasitol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1016\/S0021-9258(18)83280-X","article-title":"Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin","volume":"264","author":"Jackowski","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1128\/AAC.02640-14","article-title":"Pantothenic Acid Biosynthesis in the Parasite Toxoplasma gondii: A Target for Chemotherapy","volume":"58","author":"Mageed","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/icb.2011.97","article-title":"HDAC inhibitors in parasitic diseases","volume":"90","author":"Andrews","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1586\/eri.12.100","article-title":"Toxoplasma histone acetylation remodelers as novel drug targets","volume":"10","author":"Vanagas","year":"2012","journal-title":"Expert Rev. Anti-Infect."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20082826","article-title":"Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites","volume":"206","author":"Bougdour","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.00462-10","article-title":"Activity of the Histone Deacetylase Inhibitor FR235222 on Toxoplasma gondii: Inhibition of Stage Conversion of the Parasite Cyst Form and Study of New Derivative Compounds","volume":"54","author":"Maubon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Alday, P.H., Bruzal, I., Pou, S., Nilsen, A., Riscoe, M.K., and Doggett, J. (2016). Mechanism of Action of ELQ-316 Against Toxoplasma gondii: Evidence for Qi Site Inhibition of Cytochrome bc1. Open Forum Infect. Dis., 3.","DOI":"10.1093\/ofid\/ofw172.1797"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e01866-16","DOI":"10.1128\/AAC.01866-16","article-title":"Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii","volume":"61","author":"Alday","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acsinfecdis.8b00133","article-title":"Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc(1) and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis","volume":"4","author":"McConnell","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/jac\/dkx134","article-title":"Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis","volume":"72","author":"Ferre","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/infdis\/jiw488","article-title":"Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis","volume":"214","author":"Schaefer","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e02527-18","DOI":"10.1128\/AAC.02527-18","article-title":"Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy","volume":"63","author":"Ferre","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.actatropica.2014.09.020","article-title":"Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii","volume":"141","author":"Mossallam","year":"2015","journal-title":"Acta Trop."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cmdc.201300050","article-title":"Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii","volume":"8","author":"Stec","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.parint.2009.08.004","article-title":"Thiolactomycin analogues as potential anti-Toxoplasma gondii agents","volume":"58","author":"Jones","year":"2009","journal-title":"Parasitol. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15936","DOI":"10.1073\/pnas.1208069109","article-title":"Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis","volume":"109","author":"Doggett","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Secrieru, A., Costa, I.C.C., O\u2019Neill, P.M., and Cristiano, M.L.S. (2020). Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses. Molecules, 25.","DOI":"10.3390\/molecules25071574"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01640-17","DOI":"10.1128\/AAC.01640-17","article-title":"Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box","volume":"62","author":"Spalenka","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Murata, Y., Sugi, T., Weiss, L.M., and Kato, K. (2017). Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178203"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.12688\/f1000research.7924.1","article-title":"Recent advances in understanding apicomplexan parasites","volume":"5","author":"Seeber","year":"2016","journal-title":"F1000Research"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0020-7519(98)00076-9","article-title":"Apical organelles and host-cell invasion by Apicomplexa","volume":"28","author":"Dubremetz","year":"1998","journal-title":"Int. J. Parasitol"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpara.2008.09.013","article-title":"Intracellular survival of apicomplexan parasites and host cell modification","volume":"39","author":"Stanway","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fcimb.2020.00294","article-title":"Toxoplasma gondii Mechanisms of Entry Into Host Cells","volume":"10","author":"Portes","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1007\/s00436-019-06493-6","article-title":"Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites","volume":"118","author":"Portes","year":"2019","journal-title":"Parasitol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.micro.62.081307.162802","article-title":"Hijacking of host cellular functions by the Apicomplexa","volume":"62","author":"Plattner","year":"2008","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"a016758","DOI":"10.1101\/cshperspect.a016758","article-title":"Clathrin-independent pathways of endocytosis","volume":"6","author":"Mayor","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1017\/S0031182017001901","article-title":"The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design","volume":"145","author":"Cardew","year":"2018","journal-title":"Parasitology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nsmb.1818","article-title":"Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors","volume":"17","author":"Ojo","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1021\/jm4001314","article-title":"Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii","volume":"56","author":"Lourido","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/ml100096t","article-title":"Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii","volume":"1","author":"Murphy","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1128\/AAC.01236-15","article-title":"In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum","volume":"59","author":"Winzer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: Structure, function, and clinical significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1128\/EC.00255-07","article-title":"Make It or Take It: Fatty Acid Metabolism of Apicomplexan Parasites","volume":"6","author":"Mazumdar","year":"2007","journal-title":"Eukaryot. Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0603391103","article-title":"Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii","volume":"103","author":"Mazumdar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/mmi.13010","article-title":"The intracellular parasite Toxoplasma gondii depends on the synthesis of long-chain and very long-chain unsaturated fatty acids not supplied by the host cell","volume":"97","author":"Ramakrishnan","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1194\/jlr.M082891","article-title":"Toxoplasma gondii acetyl-CoA synthetase is involved in fatty acid elongation (of long fatty acid chains) during tachyzoite life stages","volume":"59","author":"Dubois","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1074\/jbc.M111.310144","article-title":"Apicoplast and Endoplasmic Reticulum Cooperate in Fatty Acid Biosynthesis in Apicomplexan Parasite Toxoplasma gondii","volume":"287","author":"Ramakrishnan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbiopara.2006.03.010","article-title":"Histone mediated gene activation in Toxoplasma gondii","volume":"148","author":"Sullivan","year":"2006","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1574-6976.2011.00305.x","article-title":"Mechanisms of Toxoplasma gondii persistence and latency","volume":"36","author":"Sullivan","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fcimb.2020.00289","article-title":"Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs","volume":"10","author":"Angel","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00184-5","article-title":"Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance","volume":"108","author":"McFadden","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1128\/AAC.02541-14","article-title":"Repurposing the Open Access Malaria Box To Discover Potent Inhibitors of Toxoplasma gondii and Entamoeba histolytica","volume":"58","author":"Boyom","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Patra, A.T., Hingmire, T.B., Belekar, M., Xiong, A., Subramanian, G., Bozdech, Z., Preiser, P., Shanmugam, D., and Chandramohanadas, R. (2019). Whole Cell Phenotypic Screening Of MMV Pathogen Box identifies Specific Inhibitors of Plasmodium falciparum merozoite maturation and egress. bioRxiv, 772434.","DOI":"10.1101\/772434"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acsinfecdis.8b00113","article-title":"Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro","volume":"4","author":"Radke","year":"2018","journal-title":"ACS Infect. Dis."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/9\/1960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:10Z","timestamp":1760166010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/9\/1960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["microorganisms9091960"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9091960","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}